OCKHAM BIOTECH  

Inhaled heparin for COPD & cystic fibrosis  

OWNER

(See Profile)


Sector

Therapeutics

Stage

Phase II

Country

UK

Orphan drug status and granted patents in the EU

PhIIb study showed significant clinical improvements in chronic obstructive pulmonary disease (COPD)

EMA approval to progress

Exit planned at end of phase II for cystic fibrosis

If you want to have more information or you want to review the project, you have to login or register
Contact the entrepreneur
Share your thoughts with other BioExperts

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar